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Background
Several studies of pediatric acute myeloid leukemia have described the various type-I or type-
II aberrations and their relationship with clinical outcome. However, there has been no recent
comprehensive overview of these genetic aberrations in one large pediatric acute myeloid
leukemia cohort. 
Design and Methods
We studied the different genetic aberrations, their associations and their impact on prognosis
in a large pediatric acute myeloid leukemia series (n=506). Karyotypes were studied, and
hotspot regions of NPM1, CEPBA, MLL, WT1, FLT3, N-RAS, K-RAS, PTPN11 and KIT were
screened for mutations of available samples. The mutational status of all type-I and type-II
aberrations was available in 330 and 263 cases, respectively. Survival analysis was performed
in a subset (n=385) treated on consecutive acute myeloid leukemia Berlin-Frankfurt-Munster
Study Group and Dutch Childhood Oncology Group treatment protocols.
Results
Genetic aberrations were associated with specific clinical characteristics, e.g. significantly high-
er diagnostic white blood cell counts in MLL-rearranged, WT1-mutated and FLT3-ITD-positive
acute myeloid leukemia. Furthermore, there was a significant difference in the distribution of
these aberrations between children below and above the age of two years. Non-random asso-
ciations, e.g. KIT mutations with core-binding factor acute myeloid leukemia, and FLT3-ITD
with t(15;17)(q22;q21), NPM1- and WT1-mutated acute myeloid leukemia, respectively, were
observed. Multivariate analysis revealed a ‘favorable karyotype’, i.e. t(15;17)(q22;q21),
t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22). NPM1 and CEBPA double mutations
were independent factors for favorable event-free survival. WT1 mutations combined with
FLT3-ITD showed the worst outcome for 5-year overall survival (22±14%) and 5-year event-
free survival (20±13%), although it was not an independent factor in multivariate analysis.
Conclusions
Integrative analysis of type-I and type-II aberrations provides an insight into the frequencies,
non-random associations and prognostic impact of the various aberrations, reflecting the het-
erogeneity of pediatric acute myeloid leukemia. These aberrations are likely to guide the strat-
ification of pediatric acute myeloid leukemia and may direct the development of targeted ther-
apies.
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Introduction
Acute myeloid leukemia (AML) accounts for 15-20% of
pediatric leukemias.1 Despite intensification of chemother-
apy over the last decades, only approximately 60-70% of
children with AML are cured.2 AML is not a single disease
entity, and its heterogeneity is reflected by differences in
morphology, immunophenotype, as well as cytogenetic
and molecular aberrations.3 Moreover, recurrent
(cyto)genetic aberrations are important prognostic factors
in pediatric AML and an increasing number of study
groups are using them for risk group stratification.4-5
Gilliland et al. hypothesized that the development of
AML requires at least two types of genetic events.6 Type-I
aberrations occur as mutations in hotspots of specific genes
involved in signal transduction pathways (FLT3, KIT,
NRAS, KRAS and PTPN11) which lead to uncontrolled pro-
liferation and/or survival of leukemic cells. Type-II aberra-
tions are often chromosomal rearrangements of transcrip-
tion factors resulting in the translation of fusion proteins
leading to impaired differentiation of the leukemic cells,
including PML-RARα [t(15;17)(q22;q21)], AML1-ETO
[t(8;21)(q22;q22)], CBFB-MYH11 [inv(16)(p13q22)/
t(16;16)(p13;q22)] and 11q23/MLL-rearrangements. This
hypothesis was further strengthened by observations from
mouse models that one aberration is not sufficient to
induce leukemia, but that cooperative events are needed to
develop frank leukemia. For example, knock-in of FLT3-
ITD leads to the development of a myeloproliferative dis-
order but lacks the maturation arrest typical of acute
leukemia,7 whereas co-expression with inv(16)(p13q22) or
t(15;17)(q22;q21) resulted in AML.8-9
In pediatric AML, the individual type-I or type-II aberra-
tions and their relationship with clinical outcome have
been described in several studies.4-5, 10-16 However, there has
been no comprehensive overview of the associations and
the prognostic impact of type-I and type-II aberrations in
one large cohort of pediatric AML patients. Furthermore,
over the last decade, novel molecular genetic aberrations
in pediatric AML, such as mutations in the CEBPA, NPM1
and WT1 genes, as well as partial tandem duplications in
the MLL gene (MLL-PTD), have been identified.11,13,17 The
prognostic impact of these newly identified aberrations all
together in one large pediatric AML series has not so far
been reported. Identifying prognostic factors in pediatric
AML may lead to improved risk-group stratification, and
may, therefore, have a direct impact on current and future
treatment protocols. Secondly, specific leukemogenic
aberrations may guide the development of targeted thera-
py approaches for selected patient groups.
We, therefore, performed a study on type-I and type-II
aberrations in the largest pediatric AML series so far,
which also focused on their association with clinical char-
acteristics and outcome.
Design and Methods
Study cohort
This study included 506 pediatric patients with de novo AML,
the data for whom were provided by the Dutch Childhood
Oncology Group (DCOG), the AML ‘Berlin-Frankfurt-Münster’
Study Group (AML-BFM-SG), the Czech Pediatric Hematology
(CPH) group, and the St. Louis Hospital in Paris, France.
Institutional review board approval for these studies and informed
consent was obtained according to local laws and regulations.
Each study group performed a central review of the morphology
according to the WHO/FAB classification.18 Clinical and cell-bio-
logical data, including cytogenetic results, were obtained from
these study groups and institutes. 
Survival analysis was restricted to a subset of 385 AML patients
who received relatively homogenous treatment according to
DCOG/AML-BFM 87, DCOG 92-94/AML-BFM 93, AML-BFM
98, AML-BFM 04 and MRC-12/15 protocols. Details of these treat-
ment protocols and overall outcome data have already been pub-
lished.19-24 Treatment consisted of 4 to 5 blocks of intensive
chemotherapy, using a standard cytarabine and anthracycline
backbone. Stem cell transplantation in first complete remission
was only performed in a small number of selected high-risk
patients.
Definition of gene mutations as type-I 
and type-II aberrations.
Screening of gene mutations was carried out according to the
availability of material. Mutations were determined in the hotspot
regions of NPM1 (n=337), CEPBA (n=282), MLL (i.e. partial tan-
dem duplications - PTD; n=309), WT1 (n=330), FLT3 (i.e. internal
tandem duplications - ITD; n=372) and tyrosine kinase domain
mutations (TKD; n=330), N-RAS and K-RAS (n=353), PTPN11
(n=350) and KIT (n=368), as previously described.13-14,25-29 This
resulted in screening of all type-I aberrations in 330 cases and all
type-II aberrations in 263 cases. A complete list of screened
regions per gene, primers and PCR conditions is provided in the
Online Supplementary Table S1. The ‘fusion gene’ type-II aberra-
tions, i.e. MLL-rearrangements, t(8;21)(q22;q22), inv(16)(p13q22)/
t(16;16)(p13;q22), t(15;17)(q22;q21), were mutually exclusive with
NPM1 mutations, CEBPA double mutations  and MLL-PTD aber-
rations, which suggests that these latter mutations can be consid-
ered as type-II aberrations. This is further strengthened by evi-
dence that these aberrations result in a maturation arrest; e.g. tar-
geted disruption of C/EBPα results in a selective early block of
granulocyte differentiation,30 while NPM1 mutations and MLL-
PTD disrupt the controlled expression of HOX-genes resulting in
impaired differentiation of the hematopoietic cells.31-33 Hence
NPM1 mutations, CEBPA double mutations, and MLL-PTD aber-
rations were considered to be type-II aberrations, whereas muta-
tions in FLT3, N/K-RAS, PTPN11 and KIT were considered to be
type-I aberrations. As the leukemogenic mechanism of WT1muta-
tions still needs to be clarified,34 these mutations were arbitrarily
categorized as type-I aberrations for the purposes of this study
because they overlapped with the type-II defined subtypes.
Further information concerning DNA and RNA isolation, cyto-
genetic analysis, definition of cytogenetic groups and statistical
analysis is available in the Online Supplementary Appendix.
Results
Study cohort
Characteristics of the study cohort are presented in
Table 1. Sex distribution was 57% male versus 43%
female. Median age was 8.7 years (range 0-18 years), and
the distribution according to the age categories under two
years, 2-9 years and ten years and over was 18%, 38% and
44%, respectively. The median white blood cell count
(WBC) at diagnosis was 34¥109/L (range 0-585¥109/L).
FAB-M2, -M4 and -M5 were the most common morpho-
logical subtypes in this cohort; these were 23%, 24% and
24%, respectively. Distribution according to sex, age,
WBC and FAB-morphology was comparable with the
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AML-BFM trials, i.e. the AML-BFM 93 (n=471) and 98
(n=473) trials, indicating that our cohort is representative
for pediatric AML (Online Supplementary Tables S2 and S3).
The 385 pediatric AML cases included in the survival
analysis had a 5-year probability of event-free survival
(pEFS) and overall survival (pOS) of 42±3% and 60±3%,
respectively. These survival rates are in a similar range to
those of previously published studies.35
Characteristics of pediatric AML with specific 
cytogenetic subtypes
Patients were assigned to the following cytogenetic
groups: MLL-rearranged AML (24%; 122/506),
t(8;21)(q22;q22) (13%; 64/506), inv(16)(p13q22)/t(16;16)
(p13;q22) (10%; 48/506), t(15;17)(q22;q21) (6%; 28/506),
t(7;12)(q36;p13) (1%; 7/506), t(6;9)(p23;q34) (1%; 7/506),
complex karyotype (6%; 30/506), monosomy 7 (1%;
6/506), trisomy 8 (2%; 12/506), CN-AML (17%; 84/506),
and ‘other karyotype’ (13%; 65/506) (Table 1A). In 7%
(33/506) of the cases, conventional karyotyping failed, and
neither RT-PCR nor FISH led to classification of these
patients; these cases were, therefore, assigned to the
‘unknown’ cytogenetic group. An overview of the cytoge-
netic group assignment and the mutational status of the
investigated genes of all individual patients is provided in
the Online Supplementary Table S4.  
No difference in sex distribution was seen between the dif-
ferent cytogenetic groups (Table 1A). Patients with
t(8;21)(q22;q22) presented with a significantly lower WBC
(median 13¥109/L; P<0.001), and MLL-rearranged AML
patients with a significantly higher WBC (median 63¥109/L;
P=0.001) compared with the other cytogenetic groups (Table
1A). The median ages of children with MLL-rearranged AML
(3.7 years; P<0.001), with t(7;12)(q36;p13) (0.3 years;
P<0.001) and with a complex karyotype (2.5 years; P<0.001)
were all significantly lower compared with the other cytoge-
netic groups. In contrast, children with t(8;21)(q22;q22) (11.5
years; P<0.001), t(15;17)(q22;q21) (10.2 years; P=0.03), and
t(6;9)(p23;q34) (12.8 years; P=0.03) were significantly older
compared with the other cytogenetic groups (Table 1A). 
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Table 1. Overview of baseline clinical characteristics per cytogenetic (A) and molecular (B) aberration.
(A)
Frequency Age (yr) Sex WBC (x109/L)
Cytogenetic aberration n. (%) n. median Range P value* n. % F P value* n. median range P value
MLL-rearrangements 122 (24.1) 122 3.7 0.0-17.3 <0.001 122 38 0.16 96 63 1-585 0.001
t(8;21)(q22;q22) 64 (12.6) 64 11.5 2.6-18.5 <0.001 64 42 0.85 57 13 2-320 <0.001
inv(16)(p13q22) 48 (9.5) 48 10.5 0.7-17.3 0.13 48 46 0.71 42 68 3-234 0.10
t(15;17)(q22;q21) 28 (5.5) 28 10.2 1.9-17.7 0.03 28 54 0.26 24 26 1-247 0.36
t(7;12)(q36;p13) 7 (1.4) 7 0.3 0.2-1.5 <0.001 7 71 0.25 6 55 14-227 0.38
t(6;9)(p23;q34) 7 (1.4) 7 12.8 10.3-14.9 0.03 7 43 1.00 4 96 24-120 0.21
Complex (≥3 aberrations) 30 (5.9) 30 2.5 0.1-14.4 <0.001 30 47 0.70 24 21 3-320 0.24
Monosomy 7 6 (1.2) 6 10.3 4.2-14.1 0.70 6 33 0.70 3 55 3-66 0.76
Trisomy 8 12 (2.4) 12 12.0 1.0-16.8 0.11 12 33 0.48 8 77 8-302 0.13
CN-AML 84 (16.6) 84 10.7 0.1-18.8 0.01 84 41 0.57 73 43 1-535 0.15
Other 65 (12.9) 65 8.8 0.0-18.4 0.89 64 48 0.37 54 29 1-452 0.27
Unknown 33 (6.5) 33 9.0 0.7-18.0 0.19 32 47 0.67 26 37 0-483 0.49
All cases 506 (100) 506 8.7 0.0-18.8 - 504 43 - 417 34 0-585 -
CN: cytogenetically normal; WBC: white blood cell count at diagnosis; Yr: years; %F: % female; *P values refer to the comparison of the variable between the genetic subgroup vs.
all others. Bold P values are statistically significant.
(B)
Frequency Age (yr) Sex WBC (x109/L)
Molecular aberration (%) n. median Range P value* n. % F P value* n. median range P value
NPM1mut (n=337) 7.7 26 11.0 3.6-18.8 0.03 26 58 0.14 25 43 5-230 0.83
CEBPA double mut (n=282) 6.0 17 12.0 4.0-18.5 0.08 17 59 0.15 16 60 6-388 0.38
MLL-PTD (n=309) 2.3 7 7.5 4.8-18.0 0.64 6 50 0.70 5 73 45-170 0.10
WT1mut (n=330) 8.8 29 9.2 1.9-17.8 0.47 29 38 0.52 26 86 3-354 0.03
FLT3-ITD (n=372) 18.0 67 10.1 1.6-18.8 0.008 66 46 0.88 59 74 5-535 <0.001
FLT3-TKD (n=330) 2.7 9 11.2 2.0-16.9 0.25 9 44 1.00 8 46 7-320 0.96
RAS pathway (n=348) 21.6 75 9.6 0.1-16.9 0.98 75 37 0.14 61 42 3-483 0.54
- N-RASmut (n=353) 16.1 57 9.6 0.1-16.9 0.82 57 39 0.31 46 42 4-483 0.85
- K-RASmut (n=353) 3.7 13 11.3 5.5-16.9 0.06 13 15 0.03 10 118 3-225 0.09
- PTPN11mut (n=350) 2.0 7 4.2 0.6-13.5 0.26 7 57 0.71 6 32 4-115 0.60
KITmut (n=368) 8.4 31 10.3 0.2-16.7 0.35 31 39 0.58 29 37 2-234 0.48
WBC: white blood cell count at diagnosis; yr: years; %F: % female; mut: mutation; *P values refer to the comparison of the variable between the genetic subgroup vs. the wildtypes.
Bold P values are statistically significant.
Characteristics of pediatric AML patients with type-II
gene mutations
The following frequencies of gene mutations considered
as type-II aberrations were found: NPM1 (8%; 26/337),
CEBPA double mutations (6%; 17/282) and MLL-PTD
(2%; 7/309) (Table 1B). These aberrations were mainly
present in patients with CN-AML, and were mutually
exclusive with all other type-II aberrations. No differences
were found in WBC or sex between patients carrying any
of these aberrations and those without the indicated type-
II aberration. Patients with NPM1-mutated AML were sig-
nificantly older (median 11.0 years; P=0.03) compared to
their wild-type counterparts (Table 1B).
In 180/506 (36%) cases, neither one of the type-II gene
mutations in NPM1, CEBPA and MLL, nor one of the
‘fusion gene’ type-II aberrations, i.e. MLL-rearrangements,
t(8;21)(q22;q22), inv(16)(p13q22)/t(16;16)(p13;q22),
t(15;17)(q22;q21), t(7;12)(q36;p13) and t(6;9)(p23;q34),
were identified (Figure 1A). This percentage, however, is
probably slightly lower (estimated ~33%) as we could
only screen 118 of these 180 cases for NPM1, and 101 of
the 180 cases for CEBPA and MLL-PTD mutations (Online
Supplementary Table S5). 
Characteristics of pediatric AML patients 
with type-I aberrations
For the classical type-I aberrations, i.e. mutations in
FLT3, N- and K-RAS, PTPN11 and KIT, the following fre-
quencies were found: FLT3-ITD (18%; 67/372), FLT3-TKD
(3%; 9/330), N-RAS (16%; 57/353), K-RAS (4%; 13/353),
PTPN11 (2%; 7/350) and KIT (8%; 31/368) (Table 1B).
WT1 mutations, which in this study were arbitrarily cate-
gorized as type-I aberrations, were found in 9% (29/330).
Together, we identified type-I aberrations in 185/330
(56%) cases (Figure 1B). As far as sex distribution of the
different type-I aberrations is concerned, K-RAS muta-
tions were significantly associated with male sex (85% vs.
54% of K-RAS wild-type cases; P=0.03). FLT3-ITD-
positive and WT1-mutated AML cases had a significantly
higher WBC (median 74¥109/L; P<0.001, and 86¥109/L;
P=0.03, respectively) compared to their wild-type counter-
parts. Patients with FLT3-ITD-positive AML had a signifi-
cantly higher median age (10.1 years; P=0.008) compared
to their wild-type counterparts (Table 1B). 
Non-random associations between type-I 
and type-II aberrations in pediatric AML
An overview of the associations between the type-I and
Figure 1. Distribution
of the different type-I
and type-II aberrations
in pediatric AML. The
heterogeneity of pedi-
atric AML is reflected
by the presence of the
different type-I and
type-II genetic aberra-
tions. However, in a
large number of cases
the type-II (A) or type-I
(B) aberrations have
not yet been identified.
A B
Table 2A. Univariate analysis for survival parameters of pediatric AML.
pEFS pOS
Hazard Hazard
Ratio 95% CI P value Ratio 95% CI P value
Type-II aberration
MLL-rearrangement 1.3 1.0-1.8 0.06 1.4 1.0-2.0 0.05 
t(8;21)(q22;q22) 0.7 0.4-1.0 0.05 0.4 0.2-0.8 0.005
inv(16)(p13q22) 0.2 0.1-0.4 <0.001 0.1 0.0-0.4 0.001
t(15;17)(q22;q21) 0.7 0.3-1.3 0.24 0.7 0.3-1.7 0.44
NPM1mutation 0.7 0.4-1.2 0.19 0.8 0.4-1.7 0.61
CEBPA double mutation 0.5 0.2-1.2 0.13 0.3 0.1-1.2 0.10
Type-I aberration
FLT3-ITD 1.3 0.9-1.9 0.17 1.3 0.9-2.0 0.21
WT1mutation 2.1 1.3-3.4 0.002 2.0 1.2-3.5 0.01
WT1mutation & FLT3-ITD 1.1 1.0-1.1 0.009 1.1 1.0-1.2 0.007
RAS-pathway mutation 1.0 0.7-1.4 0.89 0.8 0.5-1.4 0.47
KITmutation 0.6 0.4-1.1 0.11 0.6 0.3-1.3 0.18
WBC
>50¥109/L 1.4 1.0-1.8 0.03 1.6 1.2-2.3 0.006
Age
≥2 years 0.9 0.7-1.3 0.72 0.8 0.6-1.2 0.37
≥10 years 0.9 0.7-1.1 0.31 0.9 0.6-1.2 0.47
pEFS: probability of event-free survival; pOS: probability of overall survival; WBC: white blood
cell count at diagnosis.
Table 2B. Multivariate analysis for survival parameters of pediatric AML.
pEFS pOS
Hazard Hazard
Ratio 95% CI P value Ratio 95% CI P value
Type-II aberration
Favorable karyotype 0.3 0.2-0.5 <0.001 0.2 0.1-0.5 <0.001
NPM1 mutation 0.4 0.2-0.9 0.02 0.6 0.3-1.4 0.21
CEBPA double mutation 0.3 0.1-0.8 0.02 0.2 0.1-0.9 0.03
MLL-rearrangement 1.2 0.7-1.9 0.58 1.5 0.9-2.6 0.16
Type-I aberration
FLT3-ITD 1.2 0.8-2.0 0.40 1.3 0.7-2.3 0.43
WT1mutation 1.7 0.8-3.3 0.14 1.7 0.8-3.8 0.17
WT1 & FLT3-ITD 1.0 0.9-1.1 0.62 1.0 0.9-1.1 0.78
WBC
>50¥109/L 1.2 0.8-1.7 0.40 1.5 0.9-2.3 0.09
Age
≥10 years 1.2 0.9-1.8 0.27 1.3 0.8-1.9 0.32
pEFS: probability of event-free survival; pOS: probability of overall survival; WBC: white blood
cell count at diagnosis; favorable karyotype includes t(8;21)(q22;q22), inv(16)(p13q22) and
t(15;17)(q22;q21).
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type-II aberrations is presented in the Online Supplementary
Table S5. Although FLT3-ITD mutations were identified in
almost all type-II defined subtypes, the majority (42%)
were restricted to cases with t(15;17)(q22;q21),MLL-PTD
and NPM1 mutations, in which 64%, 57% and 39%,
respectively, harbored an FLT3-ITD (Figure 2). It is inter-
esting to note that FLT3-ITD was also simultaneously
present in 41% of the WT1-mutated cases. For FLT3-TKD
mutations, which were far less frequent in pediatric AML,
the highest frequencies were found in the MLL-PTD
(17%) and t(15;17)(q22;q21) (10%) subtypes.
KIT mutations clearly associated with core-binding fac-
tor AML (CBF-AML), i.e. t(8;21)(q22;q22) and
inv(16)(p13q22) /t(16;16)(p13;q22) (P<0.001). They were
observed in 31% of t(8;21)(q22;q22) cases and in 28% of
the inv(16)(p13q22) /t(16;16)(p13;q22) cases (Figure 2).
The N-RAS, K-RAS and PTPN11 gene mutations, com-
bined together as RAS-pathway activating mutations,
showed an equal distribution among the patients with dif-
ferent type-II aberrations. The exception was the
t(15;17)(q22;q21) subtype, in which no RAS-pathway
mutations were observed, except for only one PTPN11
mutation. Interestingly, K-RAS mutations, which were
four times less frequent than N-RAS mutations, were
more frequently seen in MLL-rearranged AML and in
CBF-AML, while N-RAS mutations were most prevalent
in t(6;9)(p23;q34) and NPM1-mutated AML. In MLL-
rearranged AML, 43% carried one of the investigated
type-I aberrations, of which the majority were RAS-path-
way aberrations (33%; Figure 2).
WT1 mutations were mainly present in t(6;9)(p23;q34)-
AML (33%), CEBPA double-mutant AML (18%) and the
subtype with ‘other/unknown’ type-II aberrations (20%).
The distribution of genetic aberrations is highly 
correlated with age in pediatric AML
We investigated the frequency of genetic subtypes,
according to the age categories 0-2 years, 2-5 years, 5-10
years, 10-15 years, and 15 years and older (Online
Supplementary Figure S1A-B). The largest differences in
genetic aberrations were detected between children under
two years of age and children two years of age and over.
We, therefore, focused further on these 2 age groups
(Online Supplementary Figure S1C-D). In children under
two years of age, significantly higher frequencies of MLL-
rearrangements and complex karyotypes were observed
when compared with children two years of age and over:
51% versus 18%; P<0.001, and 13% versus 4%; P=0.001,
respectively. Furthermore, the youngest age category
included all 7 patients with a t(7;12)(q36;p13) (P<0.001). In
contrast, in this age category t(8;21)(q22;q22) was not
observed, but this translocation was found in 15%
(P<0.001) of children two years of age and over. The
t(15;17)(q22;q21) was only present in a single case under
two year of ages (1.9 years; 1%) but occurred significantly
more often in children two years of age and over (7%;
P=0.04). Furthermore, in children two years and over, a
higher frequency of CN-AML was found compared with
children under two years of age (respectively 19% vs. 6%,
P=0.002) (Online Supplementary Figure S1C). NPM1, CEBPA
and MLL-PTD aberrations were not detected in any of the
patients under two years of age. In both age categories (<2
years and ≥2 years) the percentage of ‘other/unknown’
type-II aberrations was about one-third that of the AML,
but there was a clear difference in the distribution of the
different type-II aberrations (Online Supplementary Figure
S2A).
In children two years of age and over, a significantly
higher frequency of FLT3-ITD was found (21% vs. 3% in
children <2 years; P=0.001), and a trend was observed for
a higher frequency of WT1 mutations in patients two
years of age and over (10% vs. 2% in children <2 years;
P=0.06). Furthermore, all FLT3-TKD (n=9) and K-RAS
mutations (n=13) were found in children two years of age
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Figure 2. Type-I aberrations per type-II defined subtype. Distribution of the different type-I aberrations according to the different type-II
defined subtypes including more than 10 cases, i.e. MLL-rearrangements, t(8;21), inv(16), t(15;17), NPM1-mutated and CEBPA double mutat-
ed AML.
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and over, although this did not reach statistical signifi-
cance. In contrast, both age categories included almost
similar frequencies of N-RAS (15-20%), PTPN11 (2-3%)
and KIT mutations (5-10%) (Online Supplementary Figures
S1D and S2B). When RAS-pathway aberrations were
taken together, this pathway was affected at a similar fre-
quency in both age categories (22% vs. 21% in children <
2 years and ≥2 years of age, respectively). In children
under two years of age, 67% of the cases did not harbor
one of the investigated type-I aberrations (i.e. FLT3-ITD,
FLT3-TKD, NRAS, KRAS, PTPN11, KIT or WT1) versus
only 40% in children two years of age and over (P<0.001).
The difference between these age categories could largely
be explained by the frequency of FLT3-ITD, which was
only sporadically found in children under two years of age
(Online Supplementary Figure S2B).
Clinical outcome of pediatric AML according 
to type-I and type-II aberrations
Survival analysis was only performed for the type-I and
type-II defined subtypes containing more than 10 cases.
For the type-II aberrations, this included MLL-rearrange-
ments, t(8;21)(q22;q22), inv(16)(p13q22)/t(16;16)
(p13;q22), t(15;17)(q22;q21),  as well as NPM1- and
CEBPA-double mutated cases. All other cases were
grouped together and considered ‘other/unknown’ type-II
aberrations (Table 2A). The Kaplan-Meier curves showed
large differences between the different type-II aberrations
for 5-year pOS, 5-year pEFS, and 5-year CIR (Figure 3A-
C). Patients carrying an inv(16)(p13q22)/t(16;16)(p13;q22)-
AML showed the most favorable outcome with a 5-year
pOS, 5-year pEFS, and 5-year CIR of 97±3%, 76±8% and
19±7%, respectively. MLL-rearranged AML and the group
with ‘other/unknown’ type-II aberrations showed the
worst outcome with 5-year pOS of 56±5% and 40±5%,
respectively, 5-year pEFS of 38±5% and 26±4%, respec-
tively, and 5-year CIR of 38±5% and 51±5%, respectively.
Interestingly, cases with a t(8;21)(q22;q22) had a relatively
high 5-year CIR of 47±8%; this seemed to be related to
concurrent KIT mutations, although numbers were too
small to draw definitive conclusions. Cases with a
t(15;17)(q22;q21) only had a 5-year CIR of 7±7%. For sur-
vival analysis of the type-I aberrations, cases with various
RAS-pathway aberrations were combined. WT1-mutated
AML cases were analyzed according to their FLT3-ITD
status. All other cases were grouped together as
‘other/unknown’ type-I cases for the analysis. The Kaplan-
Meier curves showed differences in 5-year pOS, 5-year
pEFS, and 5-year CIR for the different type-I aberrations
(Figure 3D-F). Cases with a combined WT1 mutation and
FLT3-ITD showed the worst prognosis with 5-year pOS
of 22±14%, 5-year pEFS of 20±13%, and 5-year CIR of
50±17%.
Independent prognostic factors in pediatric AML
In order to reduce the number of variables in a multi-
variate Cox’s proportional hazard model, CBF-AML and
t(15;17)(q22;q21) were grouped together as the variable
‘favorable karyotype’ (Table 2B). The following variables,
which were significant in univariate analyses and/or com-
monly used in pediatric AML (WBC>50¥109/L and age
>10 years), entered the model: ‘favorable karyotype’,
MLL-rearrangements, NPM1 mutations, CEBPA double
mutations, FLT3-ITD, WT1mutations, the combination of
WT1 mutation plus an FLT3-ITD, WBC and age over ten
years. This model identified favorable karyotype (hazard
ratio (HR) 0.3, P<0.001), NPM1 mutations (HR 0.4,
P=0.02) and CEBPA double mutations (HR 0.3, P=0.02) as
independent prognostic factors for pEFS. For pOS, favor-
able karyotype was an independent prognostic factor (HR
0.2, P<0.001). Furthermore, CEBPA double mutations (HR
0.2, P=0.03) independently predicted favorable pOS.  
Discussion
Unraveling the genetics of pediatric AML provides a
basis on which to improve risk group stratification.
Furthermore, specific genetic aberrations could direct the
development of targeted therapy approaches. The low
incidence of pediatric AML makes it difficult to describe
the relevance of these aberrations, and published data
often focus on only one specific aberration. This study
describes for the first time a large cohort of pediatric AML
cases characterized for various cytogenetic and molecular
genetic aberrations, allowing the comprehensive study of
non-random associations, and their correlation with clini-
cal characteristics and outcome.  
We confirmed the non-random associations previously
described between the different types of aberrations, e.g.
KIT mutations with CBF-AML and FLT3-ITD with
t(15;17)(q22;q21).36-37 Moreover, FLT3-ITD significantly
associated with NPM1-mutated (39%) and with WT1-
mutated AML (41%). It is interesting to note that the asso-
ciation of FLT3/ITD was not correlated with a specific type
of NPM1 or WT1mutation (data not shown). As AML is like-
ly to result from a multistep pathogenesis, it is conceivable
that FLT3/ITD and WT1 mutations are associated with
additional aberrations, and it has recently been shown that
their combination is frequently present in the rare subtype
of adult AML harboring NUP98-rearrangments.38 Overall,
the majority of type-I aberrations showed an unequal dis-
tribution over the different type-II defined subtypes.
Although MLL-rearranged AML harbored one of the low-
est frequencies of type-I aberrations (43%), mutations in
the RAS-signaling pathway interestingly represented the
vast majority in MLL-rearranged AML.
Striking differences in genetic subtypes were found
between children younger and older than two years at
diagnosis of AML. Very young children with AML were
characterized by a high frequency of MLL-rearrangements
(51%), as previously reported.5 Furthermore, they were
characterized by a higher frequency of complex kary-
otypes, the exclusive presence of t(7;12)(q36;p13), and low
frequencies or even total absence of t(8;21)(q22;q22),
t(15;17)(q22;q21) and CN-AML. Moreover, the increasing
incidence of CN-AML in childhood is continued into
adulthood, in which CN-AML is present in approximately
45% of AML cases, whereas MLL-rearrangements are rare
in adult AML.39 We did not observe any difference in out-
come between the age categories under two years and
over two years. A recent large German study showed in
more detail that adolescents (13-21 years) had a slightly
inferior outcome compared to younger children, but no
difference was seen between infants (0-2 years) and young
children (2-13 years).40 Although this does not suggest that
different treatment strategies based on age are of any ben-
efit, it is conceivable that the biological differences may
lead to different treatment strategies for these age cate-
gories in the future. 
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Besides the different frequencies of several cytogenetic
aberrations between pediatric AML and adult AML (see
above), type-II gene mutations also displayed different fre-
quencies within pediatric AML as well as between pedi-
atric and adult AML. NPM1 mutations, CEBPA double
mutations and MLL-PTD did not occur in children below
the age of two years. In line with this observation, NPM1
mutations and MLL-PTD are less frequent in pediatric
compared to adult AML (5-8% and 1-3% vs. 35% and 3-
6%, respectively). In contrast, CEBPA double mutations
display relatively similar frequencies (3-6% vs. 4-10%)
between children and adults. Regarding type-I aberrations,
pediatric AML cases harbor less frequently FLT3-ITD and
FLT3-TKD, but RAS-pathway aberrations (PTPN11, N-
RAS and K-RAS mutations) and KIT mutations have com-
parable frequencies.41 WT1 mutations seem to occur at a
higher frequency in pediatric versus adult AML: 8-12% ver-
sus approximately 5-7%, respectively.
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Figure 3. Survival analysis of the type-I and type-II aberrations in pediatric AML. Kaplan-Meier estimates for (A+D) pOS, (B+E) pEFS and (C+F)
CIR for the different type-II and type-I aberrations, respectively.
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Different type-I and type-II aberrations clearly had an
impact on clinical outcome. In addition to the established
favorable prognostic cytogenetic group including
t(8;21)(q22;q22), inv(16)(p13q22)/t(16;16)(p13;q22), and
t(15;17)(q22;q21), the type-II gene mutations NPM1 and
CEBPA double mutations were of independent prognostic
relevance in pediatric AML when all prognostic factors
were considered. From this, the established favorable
cytogenetic risk group in pediatric AML can be extended
with the molecular aberrations NPM1 and CEBPA double
mutations, and will now include approximately 35-40%
of pediatric AML cases. MLL-rearrangements did not have
any impact on clinical outcome, which is in agreement
with our recent report that not MLL-rearrangements per se,
but the specific MLL-translocation partners independently
predict prognosis.42 Regarding the type-I aberrations, WT1
mutations and the combination of a WT1 mutation and
FLT3/ITD characterized poor prognostic subgroups in uni-
variate analyses. These aberrations could not be shown to
have independent prognostic significance in multivariate
analyses, which might be influenced by the small num-
bers. We previously showed that this group with com-
bined FLT3-ITD/WT1 mutation had a dismal 5-year sur-
vival of 21%,13 and this was confirmed by a large pediatric
AML study from the COG.12 FLT3-ITD did not have any
prognostic value in our study, which might be influenced
by the mutant/wild-type ratio. This has been shown to
have a big influence on the prognostic impact,16 or by its
association with other favorable aberrations such as
t(15;17)(q22;q21) and NPM1 mutations. The investigation
of the impact of the different type-I aberrations within
specific subtypes of AML was restricted by small num-
bers, although KIT mutations seemed to be associated
with the relatively high relapse rate in t(8;21)(q22;q22).
However, in a large COG series, Pollard et al. recently
showed that KITmutations lacked prognostic significance
in pediatric CBF-AML in contrast to adult CBF-AM.43-44
This shows that further risk stratification in pediatric AML
based on genetic aberrations has to be further validated by
prospective pediatric studies.
Our study has implications for diagnostics in pediatric
AML, and based on their frequency, impact on outcome,
and possible target for therapy, we would currently sug-
gest to screen for the fusion genes t(8;21)(q22;q22),
inv(16)(p13q22)/t(16;16)(p13;q22), t(15;17)(q22;q21), and
MLL-rearrangements [specifically t(6;11)(q27;q23),
t(10;11)(p11.2/p12;q23) and t(1;11) (q21;q23)],42 and for
NPM1, CEBPA, WT1 and FLT3/ITD mutations, as well as
KIT mutations in CBF-AML.
Current pediatric AML treatment protocols consist of
very intensive chemotherapy regimens which induce
considerable toxicity. To further improve outcome in
pediatric AML, new treatment strategies are needed.
Different compounds targeting type-I aberrations are cur-
rently under development. The poor prognostic group
combining an FLT3/ITD and a WT1 mutation may poten-
tially benefit from simultaneously targeting these aberra-
tions. Activated FLT3 can be targeted by compounds such
as midostaurin, lestaurtanib, sorafenib, and other multi-
targeted tyrosine kinase inhibitors.45-46 However, so far
monotherapy with these agents in adult AML has shown
limited clinical activity.47-48 In combination with
chemotherapy, upregulation of FLT3-ligand might be a
newly identified resistance mechanism.49 Moreover, a
recent randomized placebo-controlled trial of sorafenib
did not show any benefit in patients in the experimental
arm.50 Therefore, we still need to see whether this strate-
gy turns out to be successful. Compounds targeting WT1
mutations are currently not available. Still, high expres-
sion of the WT1 gene is found in most AML cases, and all
WT1-mutated cases show high WT1 expression.51
Immunotherapy using a WT1-peptide vaccine is being
developed, and a phase II trial in adult AML showed
promising results.52 In general, due to the different coop-
erating genetic events in AML, monotherapy, as with
imatinib in CML (where a single fusion gene drives the
disease), does not seem to be feasible,45 and combinations
of inhibitors may be required to efficiently kill the
leukemic cells.
Intriguingly, in approximately 44% and 33-36% of pedi-
atric AML cases, respectively, none of the investigated
type-I or type-II aberrations were present. It needs to be
mentioned that we may have missed mutations outside
the screened hotspot regions, although from previous
studies we expect them to be relatively rare. Furthermore,
RUNX1 mutations were not determined but a recent
report suggests they are infrequent events in pediatric
AML.53 Over the last decade efforts have been made to
identify the remaining genetic aberrations with high-
throughput screening techniques, e.g. by genome-wide
copy number analyses (using high resolution array-CGH
and SNP-arrays), and by re-sequencing candidate genes
such as all kinase-coding genes.25, 54-56 Although the former
led to the discovery of ASXL1 and TET2mutations, it also
revealed that AML harbored only a small number of
genomic alterations compared with other cancers.56 High-
throughput sequencing of the first whole genomes of
adult AML identified mutations in the metabolites IDH1
and IDH2, and recently in the DNA methyltransferase
gene DNMT3A, which both seemed frequent in adult
AML.57-58 Interestingly, in agreement with the hypothesis
that AML results from a multistep pathogenesis, these
aberrations might add an additional class of mutations as
aberrant TET2, IDH1 and -2 and DNMT3A have been
shown to affect the epigenetic landscape of AML. Recent
studies, however, indicated that these mutations might be
rare in pediatric AML,59-61 stressing the need for separate
pediatric studies to discover the remaining genetic aberra-
tions, including aberrations in miRNA-coding genes or in
methylation of genes or their promoter regions. 
In conclusion, the heterogeneity of pediatric AML is
reflected by the presence of different age-dependent and
clinically relevant genetic aberrations, allowing prognosti-
cally relevant groups to be identified. In addition, several
non-random associations between genetic aberrations
have been observed. The addition of these aberrations will
help us to stratify pediatric AML and to direct further
development towards targeted therapies.
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